Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07200947

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. (QL1706)

A Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination With Platinum-based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Sponsor: Hebei Medical University Fourth Hospital

Conditions Locally Advanced or Metastatic Non-Small Cell Lung Cancer SMARCA4-Deficient Tumor

Interventions QL1706, nab-paclitaxel, carboplatin

Updated 1 time since 2025 Last updated: Sep 23, 2025 Started: Dec 1, 2025 Primary completion: Dec 1, 2027 Completion: Feb 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07200947, this PHASE2 trial focuses on Locally Advanced or Metastatic Non-Small Cell Lung Cancer and SMARCA4-Deficient Tumor and remains actively recruiting participants. Sponsored by Hebei Medical University Fourth Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hebei Medical University Fourth Hospital
Peking University Cancer Hospital & Institute
Zhijie Wang

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China